Yang Liu1, Nicole L Jennings1, Anthony M Dart1, Xiao-Jun Du1. 1. Yang Liu, Nicole L Jennings, Xiao-Jun Du, Experimental Cardiology Laboratory, Baker IDI Heart and Diabetes Institute, Monash University, Melbourne, Victoria 3004, Australia.
Abstract
AIM: To optimize the experimental protocols for a simple, sensitive and accurate bleeding assay. METHODS: Bleeding assay was performed in mice by tail tip amputation, immersing the tail in saline at 37 °C, continuously monitoring bleeding patterns and measuring bleeding volume from changes in the body weight. Sensitivity and extent of variation of bleeding time and bleeding volume were compared in mice treated with the P2Y receptor inhibitor prasugrel at various doses or in mice deficient of FcRγ, a signaling protein of the glycoprotein VI receptor. RESULTS: We described details of the bleeding assay with the aim of standardizing this commonly used assay. The bleeding assay detailed here was simple to operate and permitted continuous monitoring of bleeding pattern and detection of re-bleeding. We also reported a simple and accurate way of quantifying bleeding volume from changes in the body weight, which correlated well with chemical assay of hemoglobin levels (r (2) = 0.990, P < 0.0001). We determined by tail bleeding assay the dose-effect relation of the anti-platelet drug prasugrel from 0.015 to 5 mg/kg. Our results showed that the correlation of bleeding time and volume was unsatisfactory and that compared with the bleeding time, bleeding volume was more sensitive in detecting a partial inhibition of platelet's haemostatic activity (P < 0.01). Similarly, in mice with genetic disruption of FcRγ as a signaling molecule of P-selectin glycoprotein ligand-1 leading to platelet dysfunction, both increased bleeding volume and repeated bleeding pattern defined the phenotype of the knockout mice better than that of a prolonged bleeding time. CONCLUSION: Determination of bleeding pattern and bleeding volume, in addition to bleeding time, improved the sensitivity and accuracy of this assay, particularly when platelet function is partially inhibited.
AIM: To optimize the experimental protocols for a simple, sensitive and accurate bleeding assay. METHODS: Bleeding assay was performed in mice by tail tip amputation, immersing the tail in saline at 37 °C, continuously monitoring bleeding patterns and measuring bleeding volume from changes in the body weight. Sensitivity and extent of variation of bleeding time and bleeding volume were compared in mice treated with the P2Y receptor inhibitor prasugrel at various doses or in mice deficient of FcRγ, a signaling protein of the glycoprotein VI receptor. RESULTS: We described details of the bleeding assay with the aim of standardizing this commonly used assay. The bleeding assay detailed here was simple to operate and permitted continuous monitoring of bleeding pattern and detection of re-bleeding. We also reported a simple and accurate way of quantifying bleeding volume from changes in the body weight, which correlated well with chemical assay of hemoglobin levels (r (2) = 0.990, P < 0.0001). We determined by tail bleeding assay the dose-effect relation of the anti-platelet drug prasugrel from 0.015 to 5 mg/kg. Our results showed that the correlation of bleeding time and volume was unsatisfactory and that compared with the bleeding time, bleeding volume was more sensitive in detecting a partial inhibition of platelet's haemostatic activity (P < 0.01). Similarly, in mice with genetic disruption of FcRγ as a signaling molecule of P-selectin glycoprotein ligand-1 leading to platelet dysfunction, both increased bleeding volume and repeated bleeding pattern defined the phenotype of the knockout mice better than that of a prolonged bleeding time. CONCLUSION: Determination of bleeding pattern and bleeding volume, in addition to bleeding time, improved the sensitivity and accuracy of this assay, particularly when platelet function is partially inhibited.
Authors: Xinkang Wang; Patricia L Smith; Mei-Yin Hsu; Joseph A Tamasi; Eileen Bird; William A Schumacher Journal: J Thromb Thrombolysis Date: 2007-02 Impact factor: 2.300
Authors: C J Foster; D M Prosser; J M Agans; Y Zhai; M D Smith; J E Lachowicz; F L Zhang; E Gustafson; F J Monsma; M T Wiekowski; S J Abbondanzo; D N Cook; M L Bayne; S A Lira; M S Chintala Journal: J Clin Invest Date: 2001-06 Impact factor: 14.808
Authors: P Carmeliet; J M Stassen; L Schoonjans; B Ream; J J van den Oord; M De Mol; R C Mulligan; D Collen Journal: J Clin Invest Date: 1993-12 Impact factor: 14.808
Authors: Scarlett Gillespie; Paul M Holloway; Felix Becker; Francesca Rauzi; Shantel A Vital; Kirk A Taylor; Karen Y Stokes; Michael Emerson; Felicity N E Gavins Journal: Br J Pharmacol Date: 2018-07-03 Impact factor: 8.739
Authors: James Schiemer; Andrew Bohm; Li Lin; Glenn Merrill-Skoloff; Robert Flaumenhaft; Jin-Sheng Huang; Guy C Le Breton; Athar H Chishti Journal: J Biol Chem Date: 2016-11-01 Impact factor: 5.157
Authors: W Zhu; J A Buffa; Z Wang; M Warrier; R Schugar; D M Shih; N Gupta; J C Gregory; E Org; X Fu; L Li; J A DiDonato; A J Lusis; J M Brown; S L Hazen Journal: J Thromb Haemost Date: 2018-08-09 Impact factor: 5.824
Authors: Hala Chaaban; Ravi S Keshari; Robert Silasi-Mansat; Narcis I Popescu; Padmaja Mehta-D'Souza; Yow-Pin Lim; Florea Lupu Journal: Blood Date: 2015-01-28 Impact factor: 22.113
Authors: Joseph Neumeyer; Ruei-Zeng Lin; Kai Wang; Xuechong Hong; Tien Hua; Stacy E Croteau; Ellis J Neufeld; Juan M Melero-Martin Journal: Blood Adv Date: 2019-12-23
Authors: Rudy E Fuentes; Sergei Zaitsev; Hyun Sook Ahn; Vincent Hayes; M Anna Kowalska; Michele P Lambert; Yuhuan Wang; Donald L Siegel; Daniel W Bougie; Richard H Aster; Daniel D Myers; Victoria Stepanova; Douglas B Cines; Vladimir R Muzykantov; Mortimer Poncz Journal: J Clin Invest Date: 2016-02 Impact factor: 14.808
Authors: Xiaodi Chen; Dawei Song; Sakura Nakada; Joseph Qiu; Karin Iwamoto; Ray H Chen; Yow-Pin Lim; William J Jusko; Barbara S Stonestreet Journal: Curr Pharm Des Date: 2020 Impact factor: 3.116